The company's financial position has deteriorated significantly, with total debt rising to $12.3 million and equity falling to negative $1.1 million as of 2026Q1.
Vivos Therapeutics, Inc. (VVOS) balance sheet — 8-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 |
|---|
| Total Current Assets | 4.21M | 4.38M | 7.47M | 2.46M | 5.42M | 27.32M | 20.39M | 1.98M | 2.01M |
| Cash & Short-Term Investments | 1.77M | 2.03M | 6.26M | 1.64M | 3.52M | 24.03M | 18.21M | 469.35K | 1.25M |
| Cash Only | 1.77M | 2.03M | 6.26M | 1.64M | 3.52M | 24.03M | 18.21M | 469.35K | 1.25M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 1.44M | 1.58M | 430K | 202K | 457K | 1.72M | 1.52M | 955.99K | 595.19K |
| Days Sales Outstanding | 30.22 | 33.08 | 10.44 | 5.34 | 10.41 | 37.16 | 42.34 | 30.63 | 57.29 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 263.81K | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | 35.19 | - |
| Other Current Assets | 1M | 774K | 783K | 616K | 1.45M | 0 | 61 | 0 | 133.93K |
| Total Non-Current Assets | 19.93M | 20.77M | 7.81M | 8.27M | 8.3M | 6.37M | 4.93M | 5.57M | 6.19M |
| Property, Plant & Equipment | 7.45M | 7.92M | 4.38M | 4.7M | 4.78M | 2.83M | 871.6K | 1.14M | 1.28M |
| Fixed Asset Turnover | 2.62x | 2.20x | 3.43x | 2.94x | 3.35x | 5.98x | 14.99x | 10.00x | 2.96x |
| Goodwill | 8.57M | 8.57M | 2.84M | 2.84M | 2.84M | 2.84M | 2.67M | 2.67M | 3.74M |
| Intangible Assets | 3.64M | 4.04M | 370K | 420K | 302K | 341K | 270.12K | 689.15K | 1.14M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 810.63K | 785.06K | 0 |
| Other Non-Current Assets | 272K | 228K | 216K | 307K | 374K | 356K | 1.12M | 1.07M | 26.91K |
| Total Assets | 24.14M | 25.15M | 15.28M | 10.73M | 13.72M | 33.69M | 25.33M | 7.55M | 8.2M |
| Asset Turnover | 0.84x | 0.69x | 0.98x | 1.29x | 1.17x | 0.50x | 0.52x | 1.51x | 0.46x |
| Asset Growth % | 246.38% | 64.56% | 42.44% | -21.79% | -59.27% | 33.01% | 235.39% | -7.95% | - |
| Total Current Liabilities | 20.39M | 18.08M | 4.98M | 7.29M | 6.81M | 7.51M | 7.82M | 9.09M | 2.16M |
| Accounts Payable | 2.95M | 1.68M | 1.1M | 2.15M | 1.41M | 920K | 781K | 1.08M | 474.08K |
| Days Payables Outstanding | 94.57 | 88.8 | 66.66 | 141.58 | 85.76 | 78.44 | 107.45 | 144.53 | 159.98 |
| Short-Term Debt | 8.62M | 8.35M | 0 | 0 | 0 | 1.26M | 866.97K | 3.71M | 161.54K |
| Deferred Revenue (Current) | 1.51M | 479K | 896K | 2.14M | 2.93M | 2.4M | 2.94M | 2.95M | 889.51K |
| Other Current Liabilities | 8.82M | 850K | 273K | 198K | 699K | 3K | 85 | 0 | 0 |
| Current Ratio | 0.21x | 0.24x | 1.50x | 0.34x | 0.80x | 3.64x | 2.61x | 0.22x | 0.93x |
| Quick Ratio | 0.21x | 0.24x | 1.50x | 0.34x | 0.80x | 3.64x | 2.61x | 0.19x | 0.93x |
| Cash Conversion Cycle | -64.35 | - | - | - | - | - | - | -78.71 | - |
| Total Non-Current Liabilities | 7.74M | 8.63M | 2.35M | 3.03M | 2.11M | 641K | 587.06K | 1.4M | 1.22M |
| Long-Term Debt | 3.52M | 469K | 0 | 0 | 0 | 0 | 423.1K | 0 | 525K |
| Capital Lease Obligations | 10.7M | 3.95M | 1.03M | 1.52M | 1.99M | 298K | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | -112K | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 4.22M | 4.2M | 1.22M | 1.22M | 112K | 343K | 163.97K | 1.4M | 695.02K |
| Total Liabilities | 28.13M | 26.7M | 7.33M | 10.32M | 8.92M | 8.15M | 8.41M | 10.49M | 3.38M |
| Total Debt | 12.14M | 13.5M | 1.51M | 2M | 2.41M | 1.63M | 1.29M | 3.71M | 686.54K |
| Net Debt | 10.37M | 11.47M | -4.75M | 352K | -1.11M | -22.4M | -16.92M | 3.24M | -568.18K |
| Debt / Equity | -3.05x | - | 0.19x | 4.85x | 0.50x | 0.06x | 0.08x | - | 0.14x |
| Debt / EBITDA | -0.58x | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | -0.50x | - | - | - | - | - | - | - | - |
| Interest Coverage | -22.30x | - | - | - | - | -1448.14x | -123.72x | -77.00x | -80.95x |
| Total Equity | -3.99M | -1.55M | 7.95M | 411K | 4.8M | 25.54M | 16.92M | -2.94M | 4.83M |
| Equity Growth % | -502.18% | -119.49% | 1835.28% | -91.44% | -81.2% | 50.96% | 674.82% | -160.97% | - |
| Book Value per Share | -0.23 | -0.15 | 1.58 | 0.34 | 5.22 | 30.07 | 23.23 | -5.93 | 10.45 |
| Total Shareholders' Equity | -3.81M | -1.49M | 7.95M | 411K | 4.8M | 25.54M | 16.92M | -2.94M | 4.83M |
| Common Stock | 1K | 1K | 0 | 0 | 2K | 2K | 2K | 1.24K | 1.21K |
| Retained Earnings | -138.52M | -125.36M | -104.19M | -93.05M | -79.47M | -55.62M | -35.33M | -23.28M | -12.52M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | -1.5M | -1.32M | -666.67K |
| Minority Interest | -171K | -60K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying VVOS stock.
As of 2025, Vivos Therapeutics, Inc. (VVOS) had total assets of $25.2M including $4.4M in current assets.
Vivos Therapeutics, Inc. (VVOS) carries total debt of $13.5M, offset by $2.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Vivos Therapeutics, Inc. (VVOS) has total shareholders' equity (book value) of $-1.5M ($-0.15 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Vivos Therapeutics, Inc. (VVOS) reported a current ratio of 0.24x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Imminent liquidity and dilution
Metrics are mathematically derived from official filings.
Deteriorating Solvency and Equity Erosion
As reported in recent financial filings, Vivos Therapeutics' equity position has shifted into negative territory, reaching -$1.1 million in 2026Q1, a trend that underscores the persistent erosion of shareholder value driven by sustained operating losses and an inability to achieve a self-sustaining capital structure.
The transition from positive equity in 2025Q3 to a deficit in 2026Q1 suggests that the company is consuming its net worth to fund ongoing operations. Investors should monitor whether this trajectory forces a balance sheet restructuring or further dilutive equity raises to maintain basic solvency.
Rising Leverage Amid Operational Stress
Based on the company's reported figures, total debt has climbed to $12.3 million as of 2026Q1, representing a significant increase from the $1.4 million reported in 2025Q1, which indicates a growing reliance on external financing to bridge the gap between operational cash burn and revenue.
The rapid accumulation of debt relative to the company's limited asset base suggests that leverage is being used as a necessity for survival rather than a strategic tool for growth. This reliance on debt financing in the face of negative equity warrants further investigation into the company's long-term debt service capacity.
Critical Liquidity and Runway Constraints
According to the most recent quarterly data, the current ratio has plummeted to 0.27, reflecting a severe liquidity crunch where current liabilities significantly outweigh the $2.1 million in cash reserves, leaving the firm with a dangerously thin buffer against near-term operational shocks or unexpected capital requirements.
A current ratio well below 1.0 implies that the company may struggle to meet its short-term obligations without immediate capital infusion. This liquidity profile suggests that the firm's operational runway is extremely limited, necessitating a close watch on potential financing activities.
Asset Composition and Goodwill Risk
As indicated in the balance sheet, goodwill has increased to $8.6 million as of 2026Q1, representing a substantial portion of the $25.0 million in total assets, which may expose the company to future impairment risks if the underlying business units fail to meet performance expectations.
The concentration of intangible assets on the balance sheet suggests that the company's valuation is heavily reliant on the perceived future value of its acquisitions. If the clinical adoption of the Vivos System does not accelerate, these assets may be subject to write-downs that would further impair the already negative equity position.